BMC Cancer 2010, 10:281 PubMedCrossRef 7 Fuleihan Gel H, Salamou

BMC Cancer 2010, 10:281.PubMedCrossRef 7. Fuleihan Gel H, Salamoun M, Mourad YA, Chehal A, Salem Z, Mahfoud Z, Shamseddine A: Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer:

a randomized Navitoclax mouse controlled trial. J Clin Endocrinol Metab 2005, 90:3209–3214.CrossRef 8. Shapiro CL, Manola J, Leboff M: Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001, 19:3306–3311.PubMed 9. Simpson ER, Dowsett M: Aromatase and its inhibitors: significance for breast cancer therapy. Recent Prog Horm Res 2002, 57:317–338.PubMedCrossRef 10. Jansen JP, Bergman GJ, Huels J, Olson M: The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum 2011, 40:275–284. e271–272PubMedCrossRef 11. Mauri D, Valachis A, selleck chemicals llc Polyzos NP, Tsali L, Mavroudis D, Georgoulias V, Casazza G: Does adjuvant bisphosphonate in early breast cancer modify the natural course of the

disease? A meta-analysis of randomized controlled trials. J Natl Compr Canc Netw 2010, 8:279–286.PubMed 12. Hines SL, Mincey B, Dentchev T, Sloan JA, Perez EA, Johnson DB, Schaefer PL, Alberts S, Liu H, Kahanic S, Mazurczak MA, Nikcevich DA, Loprinzi CL: Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat 2009, 117:603–609.PubMedCrossRef 13. Mauri D, Valachis A, Polyzos EPZ5676 concentration IP, Polyzos NP, Kamposioras K, Pesce LL: Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis. Breast Cancer Res Treat Cobimetinib mw 2009, 116:433–439.PubMedCrossRef 14. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R, ABCSG-12 Trial Investigators, Marth C: Endocrine

therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679–691.PubMedCrossRef 15. Shapiro CL, Halabi S, Hars V, Archer L, Weckstein D, Kirshner J, Sikov W, Winer E, Burstein HJ, Hudis C, Isaacs C, Schilsky R, Paskett E: Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer 2011, 47:683–689.PubMedCrossRef 16. Hershman DL, McMahon DJ, Crew KD, Cremers S, Irani D, Cucchiara G, Brafman L, Shane E: Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2008, 26:4739–4745.PubMedCrossRef 17.

Comments are closed.